In recent years, antibody therapeutics have advanced worldwide as highly target-specific treatments and have come to play an important role across a wide range of disease areas. At the same time, growing expectations for improved therapeutic efficacy and novel mechanisms of action have driven increasing interest in next-generation modalities that extend the capabilities of antibodies. Among these, antibody-drug conjugates (ADCs), which combine the target-recognition capabilities of antibodies with potent therapeutic agents, are attracting considerable attention as a promising approach for the future of medicine.

Against this backdrop, we seek to unlock and expand the potential of antibodies to create new therapeutic approaches for areas where adequate treatment options have not yet been established.
Drawing on the expertise we have cultivated in antibody drug discovery, we remain committed to developing treatments that offer new hope to patients.